Tribune News Service
New Delhi, August 11
India will get a bit of the motion as Russia enters the final mile of manufacturing the world’s first COVID-19 vaccine.
The Phase three medical trials might be held in lots of international locations, together with India, Saudi Arabia, the UAE, Brazil and the Philippines. This might be adopted by mass manufacturing in different international locations in partnership with native financing corporations.
“The countries identified include India besides South Korea, Brazil, Saudi Arabia, Turkey and Cuba,” stated CEO of Russia Direct Investment Fund (RDIF) Kirill Dmitriev.
The plan is to ramp up the vaccine manufacturing to 20 crore doses by the top of 2020, excluding 30 crore doses in Russia, stated Dmitriev whose fund was performing a crucial operate of bankrolling the analysis.
India was among the many first lot of 20 international locations that had expressed curiosity in acquiring the Sputnik V, he stated.
India already has had fruitful partnerships up to now with the US, each in provide chain administration and joint analysis.
External Affairs Minister S Jaishankar and US Secretary of State Mike Pompeo have mentioned the necessity to strengthen international pharmaceutical and healthcare manufacturing and provide chains, an space the place Russia doesn’t have conventional experience.
According to Dmitriev, the outcomes of the primary two phases of medical trials, to be printed this month, will present detailed details about the vaccine.
India’s Serum Institute, Panacea Biotech, Shanta Biotech and Biological E Limited are in line for taking on manufacturing orders.